Latest / Peptides Weekly / Ep 6: Thirty-nine percent of GLP-1 users reported nail detachment, versus nine percent of controls.

Transcript

Ep 6: Thirty-nine percent of GLP-1 users reported nail detachment, versus nine percent of controls. · Peptides Weekly

• 0:00
  39% of glp-1 users reported nail detachment versus 9% of controls. This is Peptides Weekly, episode
• 0:07
  6. Education and evidence, never-dosing advice. After that comparison, a surgery record, a
• 0:13
  petition on unapproved peptides, a loophole fight, a mouse result, and this week's look
• 0:18
  at research use products. Charles Taib's group brought a cross-sectional comparison, not
• 0:24
  a randomized trial to the European Academy of Dermatology and Veneriology Congress 2026.
• 0:30
  Lab Roots reports that they compared 575 GLP-1 users with 1,329 people who had obesity or type-2
• 0:39
  diabetes and had never taken the drugs, drawn from France, the United States, Brazil, and Mexico.
• 0:45
  Discaleration showed up in 46% of users and 17% of controls, and any nail disorder in 66% versus
• 0:53
  53%.
• 0:54
  Those gaps for detachment and discoloration stayed about two to three times as large, when
• 1:00
  the analysts kept only people who had lost weight, and again after skin disease and nutritional
• 1:05
  shortfalls were taken into account.
• 1:07
  The same people reported unusual hair loss at 50% versus 34%.
• 1:12
  Thinner hair at 42 versus 19, hair loss starting after treatment at 26 versus 12, and scalp redness
• 1:20
  about three times as often, often with itch, redness, or scaling.
• 1:24
  Tayyip called the association clear and said not everything that happens on a GLP1 is
• 1:29
  caused by the drug.
• 1:31
  About half the users said their nail trouble began before the medicine.
• 1:35
  Josephine Tolin, an anesthesiologist at McGovern Medical School at UT Health Houston, presented
• 1:41
  an observational record study on October 18th at the anesthesiology meeting in San Diego.
• 1:46
  Yahoo's account says the epic cosmos pull covered elective US operations from January
• 1:52
  2016 through December 2024 only cases longer than 60 minutes with at least a day in hospital.
• 2:00
  That pool held 2,8,601 patients and 145,610 of them about 7% were on a GLP1.
• 2:10
  After matching the users had 11% lower odds of a combined heart outcome and 8% lower odds
• 2:16
  of a combined infection outcome.
• 2:18
  The heart bucket mixed heart attacks, heart injury, strokes, and deaths.
• 2:22
  And the infection bucket mixed wound infection, urinary infection, pneumonia, and sepsis.
• 2:28
  So those odds do not belong to any single event.
• 2:31
  Emergencies, short cases, and same-day discharges were left out.
• 2:35
  A tighter match of 114,249 users, and 360,168 non-users, adjusted for diabetes and earlier
• 2:45
  opioid and NSAID use, put major heart complications at 1.0% versus 1.1%, and infections at 4.9 versus
• 2:55
  5.3%. The partnership for safe medicines filed a citizen petition on October 16, a regulatory
• 3:02
  request rather than a trial. It asks the Food and Drug Administration to block compounding by any
• 3:08
  route of seven unapproved peptides, BPC-157, KPV, TB-500, MOT-C, MEDEL-TIDE, SEMax,
• 3:18
  and Epitalon, and to set aside a July advisory vote.
• 3:22
  Agency scientists had recommended against all seven.
• 3:26
  The committee voted to allow six, and the petition says new members had financial ties
• 3:30
  to the peptide business, and that the meeting broke federal conflict rules.
• 3:34
  Examples Executive Director Shabir Imber Safdar said the scientists found no adequate characterization,
• 3:40
  extremely limited safety data, and no meaningful human evidence.
• 3:45
  Briefing papers said none of the seven had been adequately tested in human trials.
• 3:49
  The Alliance for Pharmacy compounding said in September 2026 that 503A pharmacies may not
• 3:55
  legally compound them now, and licensed pharmacies are selling them anyway.
• 3:59
  PSM bought several and four pharmacies in Texas and Pennsylvania compounded them and shipped
• 4:05
  them to California within 45 days.
• 4:08
  The filing also says the FDA has reports of two deaths after illegally compounded Reda
• 4:13
  Trutide, a separate unapproved product.
• 4:17
  A bipartisan group of lawmakers is pressing the FDA to shut a loophole used to import knock-off
• 4:22
  Reda Trutide, stat reported, and that push is a request, not new trial data.
• 4:28
  Retotrutide is an investigational obesity drug from Eli Lilly, so a knock-off import
• 4:33
  is not an approved medicine.
• 4:35
  Semiglutide and Tedu-glutide reduced immune-driven gut injury and mice, news medical reported,
• 4:41
  and a mouse result is not a human result.
• 4:44
  Semiglutide is a GLP1 receptor agonist, and this animal finding does not create a new human
• 4:49
  use.
• 4:51
  Away from the drug studies, TikTok is blocking peptide searches, EEW magazine reports, hospitals
• 4:57
  in New South Wales are seeing a surge in peptide-related presentations, the New England Times reports.
• 5:04
  Peptide Semiglutide sold without a prescription is this week's spotlight,
• 5:08
  and a public health reports paper says a legal loophole lets people buy it while the selling
• 5:12
  sites skip both the supplies and the guidance. That label is a sales description. It is not a
• 5:18
  regulator's finding that anyone checked identity, strength, sterility, or a human benefit.
• 5:23
  From September 1, 2025 through January 30, 2026, the team watched college students at the University of Connecticut and older adults try the preparation after searching online.
• 5:35
  20 adults took part, 12 men and 8 women, mean age 40, with a wide age spread. They were handed semi-glutide vials, diluent and supplies, and scored on 34 steps.
• 5:46
  This was not a treatment study, weight, glucose, and symptoms were not the outcome.
• 5:51
  Completing the steps was, they got 15 of the 34 steps right.
• 5:56
  The average score was 44%, and the spread around that average was 50%age points, so some
• 6:02
  people managed far more of the sequence than others.
• 6:05
  The mistakes lined up with a wrong dose, a needle stick, or an infection.
• 6:09
  Confidence sat at 2.3 out of 5 before the demonstration, and 1.9 after it.
• 6:14
  That dip was not statistically significant.
• 6:17
  People were unsure at the start and still unsure at the end.
• 6:20
  And most steps were still missed.
• 6:22
  The authors say untrained adults with no experience in injecting medicines could face a high risk
• 6:27
  of harm if they tried a self-administered gray market peptide semi-glutide from internet instructions
• 6:32
  alone.
• 6:33
  They also want a larger, more mixed group and the same test on other peptides sold without
• 6:38
  a prescription.
• 6:39
  Twenty people do not map the whole market.
• 6:41
  A 2026 narrative review in curious widens the frame, and it is not a trial and it enrolled
• 6:47
  nobody.
• 6:48
  It calls unregulated peptide use a public health problem carried by digital promotion.
• 6:53
  It also says peptide medicines have real roles when they are developed, prescribed, made,
• 6:58
  and watched through regulated paths.
• 7:00
  The promotion it describes aims experimental or weekly evidence peptides at fat loss, recovery,
• 7:07
  looks, cognition, performance, and longevity.
• 7:09
  The chain it traces runs through online promotion, gray market access, self injection, stacking, informal titration, uncertain product quality, muddy rules, and weak adverse event tracking.
• 7:23
  Stacking in that account means using more than one of these products together.
• 7:27
  Informal titration means changing the amount without a clinician.
• 7:31
  Those are descriptions of the sales culture, not a method.
• 7:34
  The review's worry is not legitimate peptide medicine.
• 7:37
  It is people experimenting with products whose identity, purity, potency, sterility, and safety are uncertain.
• 7:44
  A label can name a peptide while the vials' contents, strength, and cleanliness stay unknown.
• 7:50
  The review did not test a product, so it establishes no contamination rate.
• 7:54
  What it does establish as a narrative review is that those uncertainties sit on the same path as home injection and thin safety reporting.
• 8:02
  Regulated therapy in these sources is the path of development, prescription, manufacture,
• 8:08
  and monitoring.
• 8:09
  A loophole purchase of peptide semaglutide is not an approval to prepare and inject it
• 8:13
  at home.
• 8:14
  Neither paper shows that gray market peptides cause fat loss, faster healing, clearer thinking,
• 8:20
  or longer life.
• 8:21
  The 20-person exercise measured steps and confidence, not a health outcome.
• 8:26
  A low score speaks to handling risk, not to whether the peptide works.
• 8:29
  The review does not count how often products are mislabeled or harmful. It's
• 8:34
  called for clinician awareness, adverse event reporting, quality checks, clearer digital
• 8:39
  warnings, and proportionate oversight is a recommendation. Not proof those safeguards
• 8:44
  already work. One thing worth knowing is that a cross-sectional Congress comparison can
• 8:49
  tie GLP1 use to more nail and hair complaints without showing the drugs cause them. Also worth
• 8:56
  knowing, a surgical record analysis can link GLP1 use to slightly lower odds of combined
• 9:01
  heart and infection trouble after planned surgery.
• 9:04
  And that small gap in match charts is not proof the drug's protective person heading
• 9:08
  to an operation.
• 9:10
  And a small observed test can show untrained adults missing most steps with gray market peptide
• 9:15
  semi-glutide, which is a handling risk outside a prescription pathway, not evidence those
• 9:20
  products treat anything.
• 9:22
  That's peptides weekly.
• 9:23
  This show is education, not medical advice, talk to your own clinician before acting on
• 9:29
  anything you heard.
• 9:30
  I'm Patrick in Vancouver, see you next week.
• 9:33
  Quick tip from the network, try models and agents for beginners next.
• 9:37
  Artificial intelligence explains simply, for beginners and curious teens.
• 9:42
  Every Narin Network show is free at NarinNetwork.com, and if you would rather hear only your shows
• 9:47
  in your order, Narin Personal builds you a private daily addition.
• 9:51
  The details are at narennetwork.com join.
• 9:54
  This episode used AI voice synthesis of my voice.
• 9:58
  Editorial selection and analysis are my own.